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The current treatment of chronic hepatitis C is based on pegylated alpha interferon (PEG-IFN-a) and ribavirin. The aim of this
study was to identify biological and clinical variables related to IFN therapy that could predict patient outcome. The study en-
rolled 47 patients treated with PEG-IFN and ribavirin combined therapy. The interferon concentration was measured in serum
by a bioassay. The expression of 93 interferon-regulated genes in peripheral blood mononuclear cells was quantified by real-time
quantitative reverse transcription-PCR (RT-PCR) before and after 1 month of treatment. The interferon concentration in the
serum was significantly lower in nonresponders than in sustained virological responders. Moreover, a significant correlation was
identified between interferon concentration and interferon exposition as well as body weight. The analysis of interferon-
inducible genes in peripheral blood mononuclear cells among the genes tested did not permit the prediction of treatment out-
come. In conclusion, the better option seems to be to treat patients with weight-adjusted PEG-IFN doses, particularly for pa-
tients with high weight who are treated with PEG-IFN-a2a. Although the peripheral blood mononuclear cell samples are the
easiest to obtain, the measurement of interferon-inducible genes seems not be the best strategy to predict treatment outcome.
Hepatitis C virus (HCV) infection is a major health problemworldwide, affecting more than 170 million people (29).
HCV infection is a common cause of chronic liver disease, which
may progress to hepatocellular carcinoma, and it is themost com-
mon indication of liver transplantation (28). Current treatment is
based on the association between pegylated interferon (PEG-IFN)
and ribavirin (RBV). This treatment is effective in about 55% of
patients (15, 23).
Treatment outcome has been shown to be inﬂuenced by viral
factors such as the HCV RNA baseline or HCV genotype (35), as
well as by host factors such as obesity, cirrhosis, ethnic back-
ground, or ﬁbrosis (17). Recently, a genetic polymorphism near
the interleukin-28B gene encoding IFN-l3 has been associated
with the response to treatment (26, 33).
The early identiﬁcation of patients who do not respond to
PEG-IFN and RBV is a real challenge given themorbid side effects
and cost efﬁcacy of the treatment. It has been demonstrated that a
rapid virological response (RVR; deﬁned as the achievement of an
undetectable HCV RNA level after 4 weeks of treatment) can ac-
curately predict the sustained virologic response (SVR) (24). A
short duration of treatment has been proposed for these patients
(12, 38). In addition, the lack of early virological response (EVR;
deﬁned as a 2-log reduction in HCV RNA after 12 weeks of treat-
ment) is predictive of a nonresponse (NR) with 97 to 98% accu-
racy. For these patients, a prolonged treatment of up to 72 weeks
has been proposed (4).
Other parameters derived from the treatment can inﬂuence the
response, such as RBV doses or plasma concentrations. Indeed, it
is now ﬁrmly accepted that the body weight adjustment of RBV
doses increases the EVR andRVR rates (3).Hence, the study of the
pharmacokinetic parameters of RBV (such as RBV exposition or
RBV concentration in serum) suggests that they can predict the
treatment outcome (22, 25). For PEG-IFN, twomolecules are cur-
rently available, PEG-IFN-a2a, which has a large branched PEG
moiety and is administered at a ﬁxed dose of 180 mg/week, and
PEG-IFN-a2b, which has a small linear PEG structure and is ad-
ministered at a dose of 1.5 mg/kg of body weight/week. Unlike the
case for RBV, the importance of the IFN dose and/or concentra-
tion in the treatment response has not been deeply investigated
(6, 7, 13).
In this study, we have focused on identifying IFN-related fac-
tors that could inﬂuence treatment outcome. We have analyzed
the IFN concentrations in serum 1 month after the initiation of
treatment and the expression of IFN-inducible genes in peripheral
blood mononuclear cells (PBMCs) before and during treatment.
We showed that the IFN concentration in the serum could inﬂu-
ence treatment outcome and is dependent on the IFN exposi-
tion, particularly for high-weight patients. The expression of
interferon-related genes in the PBMC among our set of genes
could not predict the treatment outcome.
MATERIALS AND METHODS
Clinical protocol and patients. The study enrolled 56 patients who were
eligible for therapy, and they were recruited between September 2005 and
Received 2 September 2011 Returned for modification 21 October 2011
Accepted 18 November 2011
Published ahead of print 28 November 2011
Address correspondence to C. François, catherine.francois@u-picardie.fr.
Supplemental material for this article may be found at http://aac.asm.org/.
Copyright © 2012, American Society for Microbiology. All Rights Reserved.
doi:10.1128/AAC.05646-11
0066-4804/12/$12.00 Antimicrobial Agents and Chemotherapy p. 903–908 aac.asm.org 903
August 2007. These patients have established diagnoses of chronic hepa-
titis C virus with detectable HCV antibodies and detectable HCV RNA in
serum (COBAS TaqMan HCV test; Roche Diagnostics, Meylan, France).
Exclusion criteria were the presence of other hepatitis viruses, other he-
patic diseases, HIV coinfection, and othermedical complications. All par-
ticipants gave their informed consent, and the study was validated by the
local ethics committee (Comité de Protection de la Personne Nord-Ouest
II; number 04H21). Only 47 patients have been included in the present
study; among patients who were excluded, 6 stopped the treatment pre-
maturelywithout performing the follow-up, 1was spontaneously cured of
virus, and PBMCs were not collected for 2 patients.
HCV treatment was based on a combination of PEG-IFN and RBV. The
doses were 180 mg/week for PEG-IFN-a2a (n 5 32) and 1.5 mg/kg of body
weight/week for PEG-IFN-a2b (n 5 15). For patients infected with HCV
genotype 1 or 4, RBV doses were adjusted to the body weight (doses ranged
from800 to1,200mg)during48weeks. ForHCVpatients infectedwithHCV
genotype 2 or 3, a ﬁxed dose (800mg) of RBVwas given during 24 weeks.
Sample collection, HCV RNA quantitation, and serum IFN concen-
tration. PBMCs were collected with PAXgene RNA tubes (BD Diagnos-
tics, Le Pont de Claix, France), which contain an RNA stabilization re-
agent, and were frozen at 280°C until use. They were collected before the
initiation of treatment (d0; the time of pretreatment consultation) and 1
month after the ﬁrst injection (M1). To avoid variations in IFN concentra-
tions due to the time of the injection, PBMCs were collected 3 days after the
last injection atM1. HCVRNAwas quantiﬁed from serum before the initia-
tion of treatment (d0) and atM1, 3months after the ﬁrst injection (M3), and
6 months after the end of the treatment as described above. Interferon con-
centrations were determined from serum atM1 as previously described (14).
RNA isolation and real-time reverse transcription-PCR (RT-PCR).
RNA were extracted using the PAXgene blood RNA kit (Qiagen, Courta-
boeuf, France) as recommended by the manufacturer. RNA concentra-
tion and integrity were determined with a Nanodrop (Thermoscientiﬁc,
Illkirch, France) and an Agilent Bioanalyzer (Agilent Technologies,
Massy, France). Reverse transcription was performed using random hex-
amers and the high-capacity cDNA kit (Applied Biosystems, Courta-
boeuf, France) according to the manufacturer’s instructions. Real-time
PCR experiments were performed using an ABI Prism 7900 sequence
detection system (Applied Biosystems) andMicroﬂuidic card technology
(Applied Biosystems). In the present study, the cards were conﬁgured into
two 96-gene sets, which enabled the analysis of gene expression in two
different conditions (see Table S1 in the supplemental material). Gene
expression values were normalized according to the level of the b-actin
gene, which was determined as the best endogenous control by the soft-




Statistical analysis. A correlation analysis between IFN concentra-
tion, body weight, and IFN exposition was performed using the Mann-
Whitney, Kruskal-Wallis, or Pearson statistical test. Amultivariate logistic
regression model was used to explore the independent factors that could
be used to predict a virological response. Statistical analysis was per-
formed using GraphPad Prism5 and R software. Results were considered
signiﬁcant when P , 0.05.
IFN-regulated gene expression in PBMCs was analyzed using R-based
BRB-ArrayTools software, version 3.5.0, developed byRichard Simon and
the BRB-ArrayTools development team (32). Differentially expressed
genes were identiﬁed by a univariate two-sample t test with a random
variance model (8). Permutation P values for signiﬁcant genes (P , 0.05)
were computed based on 10,000 random permutations with a false dis-
covery rate of ,1% and with 95% conﬁdence. Class prediction analysis
was based on the compound covariate predictor, diagonal linear discrim-
inant analysis, nearest neighbor classiﬁcation, and support vector ma-
chines with the linear kernel. The prediction models incorporated genes
that were differentially expressed among genes at the 0.01 signiﬁcance
level as assessed by a random-variance t test. The leave-one-out cross-
validation method was used to compute the misclassiﬁcation rate. Binary
tree predictionwas based on the compound covariate predictor algorithm
by incorporating genes that were differentially expressed among classes at
the 0.05 signiﬁcance level as assessed by the random-variance t test. For all
statistical analyses, PCR duplicates were used separately to increase the
relevance of the results; only genes with a similar regulation of the two
probes were considered signiﬁcant.
RESULTS
Baseline characteristics of study groups. For each patient in-
cluded in the study, HCVRNAwasmeasured before the initiation
of the treatment (d0), after 1 (M1) and 3 (M3) months, at the end
of the treatment (EOT), and 6 months after EOT (designated
follow-up). Fifteen patients (32%) exhibited a sustained virolog-
ical response (SVR), 15 patients (32%) did not respond to treat-
ment (nonresponder [NR]), and 17 patients (36%) had a relapse
(responder relapser [RR]). Patients who did not have a 2 log de-
crease of HCV RNA levels at M3 (EVR2) all were nonresponders.
Among patients with undetectable HCV RNA at M1 (RVR1),
75% exhibited an SVR. Several parameters inﬂuencing the re-
sponse have been studied. As shown in Table 1, the degrees of
TABLE 1 Characteristics of the cohortd
Parameter
Result by response type
P valueNR RR SVR
No. of patients 15 17 15
Body wt, kg (means [SD]) 82.73 (15.34) 83.53 (14.05) 76.56 (11.88) 0.3789
HCV RNA baseline, log10 IU/ml (means [SD]) 6.39 (0.42) 6.43 (0.49) 5.59 (1.01) 0.0763
ALT, xN (means [SD])e 1.85 (1.18) 2.14 (1.67) 1.45 (0.80) 0.3777
Fibrosis score (means [SD]) 2.73 (1.12) 2.88 (1.06) 1.53 (1.25) 0.0130a
IFN exposition, mg/kg/wk (means [SD]) 1.70 (0.36) 2.05 (0.48) 2.34 (0.44) 0.0027b
Ribavirin dose, mg/kg/day (means [SD]) 12.54 (2.10) 12.34 (1.38) 12.88 (1.69) 0.4055
Age, yr (means [SD]) 48 (9.71) 52 (12.34) 43 (7.65) 0.1245
Sex (male/female) 10/5 13/4 12/3 0.6811
Genotype 1-4/other genotype 15/0 12/5 10/5 0.0488c
a For NR versus RR, P 5 0.7626; for RR versus SVR, P 5 0.0073; for NR versus SVR, P 5 0.0265.
b For NR versus RR, P 5 0.0149; for RR versus SVR, P 5 0.0858; for NR versus SVR, P 5 0.0026.
c By chi-squared test.
d NR, nonresponder patients; RR, responder relapser; SVR, sustained virological responder. Several parameters have been studied according to the treatment response. P values
were the results of Kruskal-Wallis tests. When this P value was signiﬁcant, a nonparametric statistical test was performed between each condition.
e N, normal.
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ﬁbrosis or IFN exposition (deﬁned as the dose of IFN per kg of
body weight) were signiﬁcantly different compared to the com-
plete response. On the contrary, body weight, serum alanine ami-
notransferase (ALT) level, and RBV dose were not signiﬁcantly
different between the types of responses.
Treatment response depends on serum IFN concentration.
For each patient, the IFN concentration was measured in the se-
rum at M1. Given the great variability in IFN concentration be-
tween patients, a statistical analysis was performed to determine if
the IFN concentration could be correlated with the treatment re-
sponse. As shown in Fig. 1A, IFN concentration at month 1 was
signiﬁcantly higher for patients having an RVR (median RVR2,
364 IU/ml; RVR1, 834 IU/ml). Moreover, patients without EVR
(Fig. 1B) or that were NR (Fig. 1C) had a lower serum IFN con-
centration (median EVR1, 488 IU/ml; EVR2, 121 IU/ml; NR, 164
IU/ml; RR, 576 IU/ml; SVR, 451 IU/ml).
To evaluate if IFN concentration could be related to IFN expo-
sition, a correlation analysis between these two parameters was
performed. As shown in Fig. 1D, these two parameters were pos-
itively and signiﬁcantly correlated (r 5 0.65;P , 1025), suggesting
that body weight inﬂuenced the interferon concentration in se-
rum. This effect was more pronounced with IFN-a2a, which was
administered independently of body weight (data not shown).
Moreover, we found that body weight was negatively correlated
with interferon concentration (Fig. 1E) (r 5 20.37; P 5 0.01).
Multivariate analysis was performed on treatment outcomes
using the two most signiﬁcant variables (i.e., ﬁbrosis and IFN ex-
position). Treatment outcome was characterized as response
(SVR patients) or nonresponse (RR and NR patients). Statistical
analysis showed that ﬁbrosis and IFN exposition were two inde-
pendent factors (P 5 0.0143 and 0.0289, respectively). The cutoff
was 2.06mg/kg/week. The odds ratio for IFN exposition was 5.862
(1.200 to 28.636)with a sensitivity of 87%and a speciﬁcity of 69%.
IFN-regulated gene signature during the first month of treat-
ment. Since differences in IFN concentration were observed dur-
ing treatment, we analyzed the expression of a set of IFN-induced
genes in PBMCs. Ninety-three genes were selected according to
the bibliographic survey and were further analyzed by RT-
quantitative PCR (9). Gene expression ratios between d0 and M1
were analyzed to identify speciﬁc gene expression patterns related
to clinically relevant groups. We ﬁrst studied the complete re-
sponse to treatment. Class comparison analysis identiﬁed only
one probe (STAT2) that differs signiﬁcantly between the SVR and
NR patients. One probe (STAT5A) was signiﬁcantly altered be-
tween RR and SVR patients, and 7 probes (4 genes) were signiﬁ-
cantly altered betweenNR and RR groups (Table 2). However, the
expression of these genes was unable to predict the treatment re-
sponse with great conﬁdence, as revealed by class prediction anal-
ysis.
Prediction of treatment outcome. The early prediction of
treatment outcomeduring therapy is of both clinical and econom-
ical interest. Thus, we performed a class comparison and predic-
tion analysis on the gene expression data generated at d0 or atM1.
The ﬁrst analysis concerned the prediction of treatment re-
sponse before the initiation of the treatment by analyzing the
mRNA levels at d0. Class comparison analysis identiﬁed two genes
FIG 1 IFN concentration and response to treatment. For each patient, the IFN concentration was measured at M1. Box plots represent the IFN concentration
according to the antiviral response atM1 (RVR1,n 5 11; RVR2;n 5 33) (A), atM3 (EVR2,n 5 8; EVR1,n 5 36) (B), and 6months after the endof the treatment
(NR, n 5 14; RR, n 5 17; SVR, n 5 14) (C). P values were the results ofMann-Whitney tests. The correlations between the IFN concentration and IFN exposition
(D) and body weight (E) are represented on the graphs. r and P values were the results of Pearson correlation tests.
IFN Concentration and Treatment Response
February 2012 Volume 56 Number 2 aac.asm.org 905
(ISGF3G and IFNAR2) that differ signiﬁcantly between the SVR
and NR patients, four genes between SVR and RR patients
(APOL1, CD4, BAK1, and NMI), and six genes between NR and
RR patients (ISGF3G, FAS, PSME1, IRF8, BAK1, and IFNAR2)
(Table 3). The induction of IRF8, IFNAR2, and ISGF3G and the
repression of BAK1 were more pronounced for RR patients, sug-
gesting that there were more differences in gene expression be-
tween RR and NR or SVR patients than between SVR and NR
groups. This observation was conﬁrmed by a binary tree classiﬁ-
cation in which NR patients clustered near the SVR group. RR
patients were identiﬁed in another cluster. As previously ob-
served, class prediction analysis using gene expression in PBMCs
did not allow a strongly reliable prediction of treatment response
(SVR from NR patients, 53% correct classiﬁcation by the com-
pound covariate predictor algorithm [P 5 0.41] using one probe;
NR from RR patients, 65% correct classiﬁcation by 1-nearest
neighbor algorithm [P 5 0.14] using six probes).
A similar analysis was performed from RNA abundances de-
termined after 1 month of treatment. Class comparison analysis
identiﬁed two genes that differ signiﬁcantly between NR and SVR
patients (FAS and IFNAR2), ﬁve genes that differ signiﬁcantly
between SVR and RR patients (MX1, STAT1,TRIM21, BAK1, and
SP110), and eight genes that differ signiﬁcantly between NR and
SVR patients (PSME1, IFNAR2, STAT1, FAS, RELB, BAK1,
TRIM21, and IRF8) (Table 4). As previously observed, BAK1 was
repressed for RR patients, and FAS, IFNAR2, and TRIM21 were
repressed in NR patients. Recapitulating our previous observa-
tion, binary tree prediction could not distinguish NR patients
from SVR patients. Accordingly, no prediction of treatment out-
come was possible with great conﬁdence (data not shown). The
genotype (1, 4, and 5 versus 2 and 3) did not inﬂuence gene ex-
pression (data not shown).
DISCUSSION
We showed that IFN concentrations in sera during treatmentwere
higher in patients presenting an SVR, an RVR, or an EVR than in
nonresponders or patients with neither RVR or EVR. Moreover,
IFN exposition, calculated as the dose of interferon per kg of
weight, and the weight also are correlated with the IFN concentra-
tion. This observation suggests that the weight of the patients in-
ﬂuences the pharmacokinetics of PEG-IFN, and that high-weight
patients had a lower IFN concentration in serum. This observa-
tion is particularly obvious for patients treated with PEG-IFN-
a2a, for which dose is not weight adjusted, because the volume of
distribution was more restricted with PEG-IFN-a2a (18), which
increases its availability in serum and target organs. However, our
results suggest that for overweight patients, this explanation is not
sufﬁcient, and that the administration of higher doses of IFN
could increase the SVR rate. For PEG-IFN-a2b, forwhich the dose
is weight adjusted, the weight had less inﬂuence on IFN concen-
tration (data not shown). These results conﬁrmed a previous
study that compared the pharmacokinetic parameters of the two








STAT2 0.77 0.0442 0.0483
SVR versus RR
STAT5A 1.17 0.0469 0.0471
NR versus RR
IRF2a 0.74 0.019 0.0174
GZMAa 0.64 0.0301 0.0305
IRF8 0.78 0.0381 0.0368
ISGF3G 1.24 0.0419 0.0435
a For these genes the two probes were signiﬁcantly regulated, and the P value is
indicated for the most signiﬁcant probe.








ISGF3G 1.3 0.004 0.0051
IFNAR2 0.81 0.018 0.0181
SVR versus RR
APOL1 1.28 0.007 0.0081
CD4 0.78 0.017 0.0162
BAK1 3.72 0.019 0.0219
NMI 0.78 0.03 0.03
NR versus RR
ISGF3G 1.18 0.0031 0.0037
FAS 0.68 0.0034 0.0034
PSME1 0.75 0.05 0.0049
IRF8 0.62 0.008 0.006
BAK1 3.82 0.02 0.03
IFNAR2 0.81 0.029 0.03
a For all genes the two probes were signiﬁcantly regulated, and the P value is indicated
for the most signiﬁcant probe.








FAS 0.78 0.007 0.0089
IFNAR2 0.87 0.035 0.0351
SVR versus RR
MX1 0.71 0.001 0.0017
STAT1 0.78 0.013 0.0137
TRIM21 0.81 0.014 0.0137
SP110 0.73 0.03 0.0128
BAK1 2.9 0.03 0.03
NR versus RR
PSME1 0.74 0.006 0.0054
IFNAR2 0.81 0.006 0.0048
STAT1 0.79 0.007 0.0051
FAS 0.76 0.012 0.0117
RELB 1.5 0.014 0.015
BAK1 3.4 0.017 0.02
TRIM21 0.8 0.025 0.024
IRF8 0.77 0.039 0.038
a For all genes the two probes were signiﬁcantly regulated, and the P value is indicated
for the most signiﬁcant probe.
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PEG-IFNs. A decrease in drug exposure was observed with an
increase in body weight for PEG-IFN-a2a only (31).
The small number of patients who presented a lack of RVR or
EVR in our study can inﬂuence the statistical results, but for pa-
tients with a lack of EVR, all patients but one had an IFN concen-
tration lower than 200 IU/ml. For these patients, the measure of
the IFN concentration could be useful for adapting the doses of
IFN and modifying the outcome.
This hypothesis was supported by a clinical study that com-
pared responses following PEG-IFN-a2a treatments of 180 to 270
mg/week in obese patients (5). In that study, a dose of 270mg/week
increased the IFN concentration in serum, and the SVR rate was
14%. Few studies suggested that IFN concentrationwas important
for the response independently of weight. This was demonstrated
with true nonresponder patients infected by HCV genotype 1
treated with higher doses of PEG-IFN-a2a (11). The area under
the serumconcentration-time curve of PEG-IFN-a2a increased in
a dose-dependentmanner andwas associated with an SVR.More-
over, PEG-IFN-a2a concentration was associated with the SVR in
HCV/HIV coinfected patients (21). Nevertheless, this result was
not conﬁrmed by Asahina et al. in a cohort of HCV-infected pa-
tients (1). The study was realized with weight-adjusted PEG-IFN-
a2b. This measure of interferon activity gives additional informa-
tion on treatment efﬁcacy and perhaps is more exact than an
immunological assay.
Singular results were obtained by studying the expression of
IFN-regulated genes in PBMCs at M1. As the response was corre-
lated with IFN concentration, it was legitimate to assume that the
serum IFN concentration could inﬂuence the IFN-regulated gene
expression. In fact, the gene expression in PBMCswas not directly
correlated with the interferon concentration (data not shown)
and was not easily available to predict the response with great
conﬁdence.
Other groups described that gene expression in PBMCs was
predictive of treatment outcome (10, 36). One group demon-
strated that the expression of STAT6 and SOCS1 was predictive of
the SVR in pretreatment samples (36). These genes were not in-
cluded in our assay. A second group identiﬁed four genes
(TNFAIP6, MT2A, IFIT2, and CCRL2) regulated early during the
treatment (12 h after the initiation of therapy) that could be pre-
dictive of the response (10). These results were not conﬁrmed by
another group (27), and we did not conﬁrm these results for
IFIT2. The great variability in the results could be explained in
part by differences in the timing of the analysis, i.e., before or
during treatment, after 1 month, or earlier.
Indeed, IFN gene expression in the liver was more informative
than that in PBMCs (2, 27, 30), suggesting that the treatment of
chronic HCV infection has a strong local hepatic effect on the IFN
system. This could be because the IFN concentration (always
.100 UI/ml in serum) was sufﬁcient to induce the interferon-
stimulated genes, and the difference of induction between 100 and
1,000 IU/ml did not change the induction in PBMCs. However,
the concentration in serum could inﬂuence the concentration in
the liver and then the induction of ISG in hepatocytes.
In conclusion, it would be interesting to treat patients with
weight-adjusted doses of PEG-IFN, particularly for overweight
patients, to increase the IFN concentration in the serum. This
concentration could inﬂuence antiviral efﬁcacy in the liver. Gene
induction in PBMCs did not reﬂect the antiviral efﬁcacy in the
liver. A conﬁrmation of this study with a greater number of pa-
tients is necessary, but these results are already signiﬁcant.
Two direct-acting antiviral agents (DAAs) are available. Boce-
previr and telaprevir are two inhibitors of the NS3 protease and
are administered in combination with PEG-IFN and RBV, in-
creasing the response rate. Many other DAAs (anti-NS3, anti-
NS5B, and anti-NS5A) are in trial alone or in combination with
IFN and RBV. Several trials report that a combination of DAAs
could efﬁciently decrease HCV replication without IFN and RBV
(16, 19, 37). Nevertheless, the long-term efﬁcacy seems to be re-
lated to the presence of PEG-IFN and RBV, at least to avoid resis-
tance to DAA (20).
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